Citations (56)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Tomoyuki Tatenuma & Hiroshi Miyamoto. (2023) Profile of Relugolix in the Management of Advanced Hormone-Sensitive Prostate Cancer: Design, Development, and Place in Therapy. Drug Design, Development and Therapy 17, pages 2325-2333.
Read now
Read now
Meghan K. McInnis & Caroline F. Pukall. (2023) Sexual script flexibility after a prostate cancer diagnosis: Implications for sexual satisfaction. Journal of Psychosocial Oncology 41:3, pages 267-276.
Read now
Read now
Charles F. Polotti, Christopher J. Kim, Nadiya Chuchvara, Alyssa B. Polotti, Eric A. Singer & Sammy Elsamra. (2017) Androgen deprivation therapy for the treatment of prostate cancer: a focus on pharmacokinetics. Expert Opinion on Drug Metabolism & Toxicology 13:12, pages 1265-1273.
Read now
Read now
Taichi Mizushima, Kathleen A. Tirador & Hiroshi Miyamoto. (2017) Androgen receptor activation: a prospective therapeutic target for bladder cancer?. Expert Opinion on Therapeutic Targets 21:3, pages 249-257.
Read now
Read now
Articles from other publishers (52)
Shangrong Wu, Xudong Ma, Zhengxin Liang, Yuchen Jiang, Shuaiqi Chen, Guangyu Sun, Kaifei Chen & Ranlu Liu. (2023) Development and validation of a nomogram for predicting osteoporosis in prostate cancer patients: A cross‐sectional study from China. The Prostate 83:16, pages 1537-1548.
Crossref
Crossref
Guang Yang, Qi Pan, Yang Lu, Junlong Zhu & Xin Gou. (2023) miR-29a-5p modulates ferroptosis by targeting ferritin heavy chain FTH1 in prostate cancer. Biochemical and Biophysical Research Communications 652, pages 6-13.
Crossref
Crossref
Jiuzhou Chen, Yan Yuan, Miao Fang, Youqi Zhu, Xueqing Sun, Yufei Lou, Yong Xin & Fengjuan Zhou. (2023) Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A systematic review and meta-analysis. Frontiers in Endocrinology 13.
Crossref
Crossref
J. C. Angulo, J. P. Ciria Santos, A. Gómez-Caamaño, R. Poza de Celis, J. L. González Sala, J. M. García Garzón, J. A. Galán-Llopis, M. Pérez Sampietro, V. Perrot, J. Planas Morin, José Manuel Abascal, Víctor Barrond, Antonio Benedicto, Ana Carballo, José Ramón Cortiñas, Manuel Fernández, Eduardo Ferrer, Pablo Luís Guzmán, Miguel Ángel López, José Carlos Martínez, Carlos Olivier, Paula Peleteiro, Pedro Julio Pérez, Daniel Pesqueira, José Ponce, Manuel Ruibal, Josep Segarra, Eduardo Solsona, José Francisco Suárez, José Rosa, Ángel Tabernero, Félix Vesga & Almudena Zapatero. (2022) Development of castration resistance in prostate cancer patients treated with luteinizing hormone-releasing hormone analogues (LHRHa): results of the ANARESISTANCE study. World Journal of Urology 40:10, pages 2459-2466.
Crossref
Crossref
Wenjing Shi, Haixiao Di, Bo Pang, Huixin Jin, Hongtao Liu, Bo Qiu, Bingnan Ren & Guoxun Pang. (2022) Comparative pharmacokinetic study of bicalutamide administration alone and in combination with vitamin D in rats. Acta Chromatographica 34:4, pages 453-460.
Crossref
Crossref
Rebecca A. Sager, Sarah J. Backe, Elham Ahanin, Garrett Smith, Imad Nsouli, Mark R. Woodford, Gennady Bratslavsky, Dimitra Bourboulia & Mehdi Mollapour. (2022) Therapeutic potential of CDK4/6 inhibitors in renal cell carcinoma. Nature Reviews Urology 19:5, pages 305-320.
Crossref
Crossref
MAkcay Celik, H Erdem, S Cankaya & YKasko Arici. (2022) Differences in SUV39H1 and androgen receptor distribution in adenomyomatous hyperplasia and prostatic adenocarcinoma. Nigerian Journal of Clinical Practice 25:9, pages 1387.
Crossref
Crossref
Rajeev K. Singla, Pooja Sharma, Ankit Kumar Dubey, Rohit Gundamaraju, Dinesh Kumar, Suresh Kumar, Reecha Madaan, Richa Shri, Christos Tsagkaris, Salvatore Parisi, Shikha Joon, Shailja Singla, Mohammad Amjad Kamal & Bairong Shen. (2021) Natural Product-Based Studies for the Management of Castration-Resistant Prostate Cancer: Computational to Clinical Studies. Frontiers in Pharmacology 12.
Crossref
Crossref
Guoqiang Sun, Dawei Rong, Zhouxiao Li, Guangshun Sun, Fan Wu, Xiao Li, Hongyong Cao, Ye Cheng, Weiwei Tang & Yangbai Sun. (2021) Role of Small Molecule Targeted Compounds in Cancer: Progress, Opportunities, and Challenges. Frontiers in Cell and Developmental Biology 9.
Crossref
Crossref
Fabrizio Fontana & Patrizia Limonta. (2021) Dissecting the Hormonal Signaling Landscape in Castration-Resistant Prostate Cancer. Cells 10:5, pages 1133.
Crossref
Crossref
Mobeen Rahman & Christopher C. Griffith. (2021) Salivary Duct Carcinoma. Surgical Pathology Clinics 14:1, pages 111-126.
Crossref
Crossref
Xumin Zhou, Libin Zou, Wenbin Chen, Taowei Yang, Junqi Luo, Kaihui Wu, Fangpeng Shu, Xiao Tan, Yu Yang, Shengren Cen, Chuanyin Li & Xiangming Mao. (2021) Flubendazole, FDA-approved anthelmintic, elicits valid antitumor effects by targeting P53 and promoting ferroptosis in castration-resistant prostate cancer. Pharmacological Research 164, pages 105305.
Crossref
Crossref
Beibei Zhai, Yue Li, Sudha Sravanti Kotapalli, Jeffrey Bacha, Dennis Brown, Anne Steinø & Mads Daugaard. (2020) Dianhydrogalactitol synergizes with topoisomerase poisons to overcome DNA repair activity in tumor cells. Cell Death & Disease 11:7.
Crossref
Crossref
Meghan K. McInnis & Caroline F. Pukall. (2020) Sex After Prostate Cancer in Gay and Bisexual Men: A Review of the Literature. Sexual Medicine Reviews 8:3, pages 466-472.
Crossref
Crossref
Xumin Zhou, Jinming Zhang, Xiaoping Hu, Peiqing He, Jianyu Guo, Jun Li, Tian Lan, Jumei Liu, Lilan Peng & Hua Li. (2020) Pyrimethamine Elicits Antitumor Effects on Prostate Cancer by Inhibiting the p38-NF-κB Pathway. Frontiers in Pharmacology 11.
Crossref
Crossref
Siqi Xu, Xiaoyan Wu, Zhihua Tao, Hongsheng Li, Chenliang Fan, Songjin Chen, Jianwei Guo, Yao Ning & Xuqi Hu. (2019) Effect of aberrantly methylated androgen receptor target gene PCDH7 on the development of androgen-independent prostate cancer cells. Genes & Genomics 42:3, pages 299-307.
Crossref
Crossref
Spencer Asay, Andrew Graham, Sydney Hollingsworth, Bradley Barnes, Richard V. Oblad, David J. Michaelis & Jason D. Kenealey. (2020) γ-Tocotrienol and α-Tocopherol Ether Acetate Enhance Docetaxel Activity in Drug-Resistant Prostate Cancer Cells. Molecules 25:2, pages 398.
Crossref
Crossref
Sebastian Student, Tomasz Hejmo, Aleksandra Poterała-Hejmo, Aleksandra Leśniak & Rafał Bułdak. (2020) Anti-androgen hormonal therapy for cancer and other diseases. European Journal of Pharmacology 866, pages 172783.
Crossref
Crossref
Benjamin M. Johnson, Faisal F. Y. Radwan, Azim Hossain, Bently P. Doonan, Jessica D. Hathaway‐Schrader, Jason M. God, Christina V. Voelkel‐Johnson, Narendra L. Banik, Sakamuri V. Reddy & Azizul Haque. (2018) Endoplasmic reticulum stress, autophagic and apoptotic cell death, and immune activation by a natural triterpenoid in human prostate cancer cells. Journal of Cellular Biochemistry 120:4, pages 6264-6276.
Crossref
Crossref
Yujiro Nagata, Takuro Goto & Hiroshi Miyamoto. (2019) The Role of Mineralocorticoid Receptor Signaling in Genitourinary Cancers. Nuclear Receptor Research 6.
Crossref
Crossref
Avinash De SousaAvinash De Sousa. 2019. Disulfiram. Disulfiram
9
20
.
Hiroki Ide, Satoshi Inoue, Taichi Mizushima, Guiyang Jiang, Kuang-Hsiang Chuang, Mototsugu Oya & Hiroshi Miyamoto. (2018) Androgen Receptor Signaling Reduces Radiosensitivity in Bladder Cancer. Molecular Cancer Therapeutics 17:7, pages 1566-1574.
Crossref
Crossref
Satoshi Inoue, Taichi Mizushima & Hiroshi Miyamoto. (2018) Role of the androgen receptor in urothelial cancer. Molecular and Cellular Endocrinology 465, pages 73-81.
Crossref
Crossref
Yeesha Poon, Petros Pechlivanoglou, Shabbir M.H. Alibhai, David Naimark, Jeffrey S. Hoch, Emmanuel Papadimitropoulos, Mary-Ellen Hogan & Murray Krahn. (2018) Systematic review and network meta-analysis on the relative efficacy of osteoporotic medications: men with prostate cancer on continuous androgen-deprivation therapy to reduce risk of fragility fractures. BJU International 121:1, pages 17-28.
Crossref
Crossref
J.M. Cozar, I. Robles-Fernandez, L.J. Martinez-Gonzalez, M. Pascual-Geler, Alba Rodriguez-Martinez, M.J. Serrano, J.A. Lorente & M.J. Alvarez-Cubero. (2018) Genetic markers a landscape in prostate cancer. Mutation Research/Reviews in Mutation Research 775, pages 1-10.
Crossref
Crossref
Hogyoung Kim, Amrita Datta, Sudha Talwar, Sarmad N. Saleem, Debasis Mondal & Asim B. Abdel-Mageed. (2016) Estradiol-ERβ2 signaling axis confers growth and migration of CRPC cells through TMPRSS2-ETV5 gene fusion. Oncotarget 8:38, pages 62820-62833.
Crossref
Crossref
Jing Wu, Wei-Kang Chen, Wei Zhang, Jin-Song Zhang, Jian-He Liu, Yong-Ming Jiang & Ke-Wei Fang. (2017) Network meta-analysis of the efficacy and adverse effects of several treatments for advanced/metastatic prostate cancer. Oncotarget 8:35, pages 59709-59719.
Crossref
Crossref
Javier Angulo, Ignacio Romero, María Teresa Díaz-Puente, Santos Enrech, Raúl Díez & Teresa Molina. (2017) Supervivencia del cáncer de próstata resistente a la castración en la práctica clínica y el papel del tratamiento. Revista Colombiana de Cancerología 21:2, pages 95-103.
Crossref
Crossref
Lisa M. Wu & Ali Amidi. (2017) Cognitive impairment following hormone therapy: current opinion of research in breast and prostate cancer patients. Current Opinion in Supportive & Palliative Care 11:1, pages 38-45.
Crossref
Crossref
Peng Li, Jinbo Chen & Hiroshi Miyamoto. (2017) Androgen Receptor Signaling in Bladder Cancer. Cancers 9:12, pages 20.
Crossref
Crossref
Yumiko Yokomizo, Takashi Kawahara, Yoji Nagashima, Hitoshi Ishiguro, Ikuma Kato, Masahiro Yao, Hiroshi Miyamoto & Hiroji Uemura. (2017) Lack of an association between the aPKCλ/ι expression in prostate cancer and the patient outcomes. International Journal of Surgery Case Reports 37, pages 180-182.
Crossref
Crossref
Marianne Schmid, Jesse D. Sammon, Gally Reznor, Victor Kapoor, Jacqueline M. Speed, Firas A. Abdollah, Akshay Sood, Felix K.‐H. Chun, Adam S. Kibel, Mani Menon, Margit Fisch, Maxine Sun & Quoc‐Dien Trinh. (2015) Dose‐dependent effect of androgen deprivation therapy for localized prostate cancer on adverse cardiac events. BJU International 118:2, pages 221-229.
Crossref
Crossref
Takashi Kawahara, Ali Kadhim Aljarah, Hasanain Khaleel Shareef, Satoshi Inoue, Hiroki Ide, John D. Patterson, Eiji Kashiwagi, Bin Han, Yi Li, Yichun Zheng & Hiroshi Miyamoto. (2016) Silodosin inhibits prostate cancer cell growth via ELK1 inactivation and enhances the cytotoxic activity of gemcitabine. The Prostate 76:8, pages 744-756.
Crossref
Crossref
Marianne Schmid, Julian Hanske, Praful Ravi, Nandita Krishna, Gally Reznor, Christian P Meyer, Margit Fisch, Joachim Noldus, Paul L Nguyen & Quoc-Dien Trinh. (2016) Relationship between androgen deprivation therapy and community-acquired respiratory infections in patients with prostate cancer. International Journal of Urology 23:4, pages 305-311.
Crossref
Crossref
Koji Izumi, Masataka Taguri, Hiroshi Miyamoto, Yoshinori Hara, Takeshi Kishida, Kimio Chiba, Tetsuo Murai, Kotaro Hirai, Kotaro Suzuki, Kiyoshi Fujinami, Teiichiro Ueki, Koichi Udagawa, Kazuo Kitami, Masatoshi Moriyama, Yasuhide Miyoshi, Futoshi Tsuchiya, Ichiro Ikeda, Kazuki Kobayashi, Maho Sato, Satoshi Morita, Kazumi Noguchi & Hiroji Uemura. (2014) Androgen deprivation therapy prevents bladder cancer recurrence. Oncotarget 5:24, pages 12665-12674.
Crossref
Crossref
Yuanshan Cui, Huantao Zong, Huilei Yan, Nan Li & Yong Zhang. (2014) Degarelix versus Goserelin plus Bicalutamide Therapy for Lower Urinary Tract Symptom Relief, Prostate Volume Reduction and Quality of Life Improvement in Men with Prostate Cancer: A Systematic Review and Meta-Analysis. Urologia Internationalis 93:2, pages 152-159.
Crossref
Crossref
Patrizia Limonta & Marilena Manea. (2013) Gonadotropin-releasing hormone receptors as molecular therapeutic targets in prostate cancer: Current options and emerging strategies. Cancer Treatment Reviews 39:6, pages 647-663.
Crossref
Crossref
Keith R. Solomon, Kristine Pelton & Michael R. Freeman. 2013. Prostate Cancer. Prostate Cancer
65
83
.
Eric A. Singer & Ramaprasad Srinivasan. (2012) Intravenous therapies for castration-resistant prostate cancer: Toxicities and adverse events. Urologic Oncology: Seminars and Original Investigations 30:4, pages S15-S19.
Crossref
Crossref
Elahe A. Mostaghel, Keith R. Solomon, Kristine Pelton, Michael R. Freeman & R. Bruce Montgomery. (2012) Impact of Circulating Cholesterol Levels on Growth and Intratumoral Androgen Concentration of Prostate Tumors. PLoS ONE 7:1, pages e30062.
Crossref
Crossref
Anastasios K. Goulioumis, John Varakis, Panos Goumas & Helen Papadaki. (2011) Androgen Receptor in Laryngeal Carcinoma: Could There Be an Androgen-Refractory Tumor?. ISRN Oncology 2011, pages 1-5.
Crossref
Crossref
Elisa Martín-Merino, Saga Johansson, Thomas Morris & Luis A. García Rodríguez. (2011) Androgen Deprivation Therapy and the Risk of Coronary Heart Disease and Heart Failure in Patients with Prostate Cancer. Drug Safety 34:11, pages 1061-1077.
Crossref
Crossref
Keith R. Solomon & Michael R. Freeman. (2011) The Complex Interplay Between Cholesterol and Prostate Malignancy. Urologic Clinics of North America 38:3, pages 243-259.
Crossref
Crossref
Lee W. Jones. (2011)
Evidence-based risk assessment and recommendations for physical activity clearance: cancer
1
This paper is one of a selection of papers published in this Special Issue, entitled Evidence-based risk assessment and recommendations for physical activity clearance, and has undergone the Journal’s usual peer review process.
. Applied Physiology, Nutrition, and Metabolism 36:S1, pages S101-S112.
Crossref
Crossref
P Iversen, C Karup, E van der Meulen, L B Tankó & I Huhtaniemi. (2011) Hot flushes in prostatic cancer patients during androgen-deprivation therapy with monthly dose of degarelix or leuprolide. Prostate Cancer and Prostatic Diseases 14:2, pages 184-190.
Crossref
Crossref
Tong Sun, Lee Gwo-Shu Mary, William K. Oh, Matthew L. Freedman, Mark Pomerantz, Kenneth J. Pienta & Philip W. Kantoff. (2011)
Inherited Variants in the Chemokine
CCL2
Gene and Prostate Cancer Aggressiveness in a Caucasian Cohort
. Clinical Cancer Research 17:6, pages 1546-1552.
Crossref
Crossref
Erik Wibowo, Paul Schellhammer & Richard J. Wassersug. (2011) Role of Estrogen in Normal Male Function: Clinical Implications for Patients With Prostate Cancer on Androgen Deprivation Therapy. Journal of Urology 185:1, pages 17-23.
Crossref
Crossref
Tong Sun, Gwo-Shu Mary Lee, Lillian Werner, Mark Pomerantz, William K. Oh, Philip W. Kantoff & Matthew L. Freedman. (2010)
Inherited Variations in
AR, ESR1
, and
ESR2
Genes Are Not Associated With Prostate Cancer Aggressiveness or With Efficacy of Androgen Deprivation Therapy
. Cancer Epidemiology, Biomarkers & Prevention 19:7, pages 1871-1878.
Crossref
Crossref
Christopher J. Hoimes & W. Kevin Kelly. (2009) Redefining hormone resistance in prostate cancer. Therapeutic Advances in Medical Oncology 2:2, pages 107-123.
Crossref
Crossref
Young Kwang Chae, Han-Yao Huang, Paul Strickland, Sandra C. Hoffman & Kathy Helzlsouer. (2009) Genetic Polymorphisms of Estrogen Receptors α and β and the Risk of Developing Prostate Cancer. PLoS ONE 4:8, pages e6523.
Crossref
Crossref
. (2009) Current World Literature. Current Opinion in Endocrinology, Diabetes & Obesity 16:3, pages 260-277.
Crossref
Crossref
Mark T. Fleming, Guru Sonpavde, G. Varuni Kondagunta, Matthew D. Galsky, Thomas E. Hutson & Cora N. Sternberg. (2009) Systemic therapy and novel agents for metastatic castration resistant prostate cancer. Update on Cancer Therapeutics 3:3, pages 133-145.
Crossref
Crossref